Our Partners

We plan to remain independent, growing organically by means of the value created by our expertise in Research & Development, through collaborations and partnerships with established biopharma companies.



We have partnered the product rights related to our VWF aptamer program with Suzhou Ribo Life Sciences Ltd. within Greater China, while retaining global ex-China product rights for ourselves.


Our Clinical stage VWF aptamer product candidate is being developed in partnership with the Medical University of Vienna as a pro-hemostatic agent for treatment of hereditary bleeding disorders.

Additional Discovery stage VWF aptamer drug candidates to be developed as anti-thrombotic agents for prevention of stroke in high risk populations are available for partnering.


Global product rights related to our ApDC drug candidates targeting GPC3 and HER3 are available for partnering.


© 2021 Guardian Therapeutics. All rights reserved.

Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:

Business Development Inquiries: businessdevelopment@guardian-rx.com